Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old
Language English Country United States Media print
Document type Clinical Trial, Clinical Trial, Phase II, Journal Article
PubMed
11096024
DOI
10.1086/317479
PII: CID000055
Knihovny.cz E-resources
- MeSH
- Antigens, Surface immunology MeSH
- Bacterial Vaccines MeSH
- Borrelia burgdorferi Group immunology MeSH
- Humans MeSH
- Lipoproteins * MeSH
- Lyme Disease immunology microbiology prevention & control MeSH
- Child, Preschool MeSH
- Bacterial Outer Membrane Proteins immunology MeSH
- Antibodies, Bacterial blood MeSH
- Vaccines, Synthetic adverse effects immunology MeSH
- Lyme Disease Vaccines adverse effects genetics immunology MeSH
- Check Tag
- Humans MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase II MeSH
- Clinical Trial MeSH
- Names of Substances
- Antigens, Surface MeSH
- Bacterial Vaccines MeSH
- Lipoproteins * MeSH
- OspA protein MeSH Browser
- Bacterial Outer Membrane Proteins MeSH
- Antibodies, Bacterial MeSH
- Vaccines, Synthetic MeSH
- Lyme Disease Vaccines MeSH
Two doses of a recombinant Lyme disease vaccine (15 and 30 microg) were administered to children 2-5 years old (0-1-month schedule) and were well tolerated. Both doses were highly immunogenic with geometric mean titers 1 month after vaccination of 4366 and 9877 ELISA units (EU)/mL, respectively. Nearly all subjects had antibody levels of > or = 1400 EU/mL, suggesting protective tick titre for one tick season.
References provided by Crossref.org
